Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients

Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View

(2018) Elizabeth A. Mills et al.   Frontiers in Immunology

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease

(2015) Darren M. Roberts et al.   JOURNAL OF AUTOIMMUNITY

Anti-JC virus antibody titres increase over time with natalizumab treatment

(2015) J Raffel et al.   Multiple Sclerosis Journal

Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica

(2015) Su-Hyun Kim et al.   JAMA Neurology

Anti-JC virus antibody titres increase over time with natalizumab treatment

(2015) J Raffel et al.   Multiple Sclerosis Journal

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

(2010) Chen S Tan et al.   LANCET NEUROLOGY

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE